atherosclerose vascular stiffness
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria T2D patients: * Men and women, age above 18 years * Written informed consent * Using RAAS inhibitors * Fulfils ADA criteria for diabetes o Fasting plasma glucose * 7.0 mmol/l OR o Random plasma glucose * 11.1 mmol/l OR o HbA1C * 6,5%, Inclusion criteria healthy controls: * Men and women, age above 18 years * Written informed consent * eGFR above 60 ml/min/175m2 (CKD-EPI formula)
Exclusion criteria
Exclusion criteria: Exclusion criteria T2D patients: * Type 1 diabetes * Clinically significant liver disease * Other causes for macroalbuminuria than nephropathy * Previous cardiovascular disease, defined as stable coronary artery disease or acute coronary syndrome, stroke or transient ischemic attack, peripheral artery disease * Patients who are mentally incompetent and cannot sign a Patient Informed Consent * Claustrophobia * Pregnancy or breastfeeding women. * Current active bone malignancy or in the previous 6 months * Disorders affecting bone metabolism, e.g. hyperparathyroidism, Paget's disease * Systolic blood pressure > 200 mmHg, Exclusion criteria healthy controls: * Type 1 or 2 diabetes * Micro- or macroalbuminuria * Clinically significant liver disease * Previous cardiovascular disease, defined as stable coronary artery disease or acute coronary syndrome, stroke or transient ischemic attack, peripheral artery disease * Patients who are mentally incompetent and cannot sign a Patient Informed Consent * Claustrophobia * Pregnancy or breastfeeding women. * Current active bone malignancy or in the previous 6 months * Disorders affecting bone metabolism, e.g. hyperparathyroidism, Paget's disease * Systolic blood pressure > 200 mmHg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vascular 18F-NaF uptake (proxy for vascular macrocalcification) is quantified by using target-to-background ratios (TBRs). | — |
Secondary
| Measure | Time frame |
|---|---|
| * CT assessed arterial macrocalcification using measurement of hounds field units. * Albuminuria assessed in 2 separate 24-hours urine samples * Carotid-femoral PWV assessed arterial stiffness * C-reactive protein (CRP) assessed systemic inflammation * VAT volume assessed with CT * SAT volume assessed with CT * Body weight, length, BMI * Adipokines: adiponectin and leptin * Glycemic indices: HbA1c, insulin, HOMA-IR, fasting glucose * Lipid parameters: total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apo-B, PCSK9 levels * Systolic and diastolic blood pressure * Kidney function and degree of albuminuria assessed using 24-hours urine creatinine clearance and albumin-to-creatinine ratio (ACR) * Plasma calcium phosphate metabolism plasma markers, including calcium, albumin, phosphate, vitamin D3, fetuin A, klotho, fibroblast growth factor 23, parathormone, serum calcification propensity score (T50). | — |
Countries
Netherlands
Outcome results
None listed